Literature DB >> 23743624

Do impaired memory, cognitive dysfunction and distress play a role in methotrexate-related neutropenia in rheumatoid arthritis patients? A comparative study.

Omer Nuri Pamuk1, Bunyamin Kisacik, Gulsum Emel Pamuk, Ahmet Mesut Onat, Mehmet Sayarlioglu, Salim Donmez, Yavuz Pehlivan, Edward C Keystone.   

Abstract

We evaluated the roles of sociocultural status, distress and cognitive functions in rheumatoid arthritis (RA) patients who developed methotrexate (MTX)-related neutropenia. The data of 37 RA patients with MTX-related neutropenia who were being followed up at 3 centers were evaluated. The control group included 74 RA patients. The clinical features, biochemical tests and treatment modalities of the patients were obtained from hospital files. The mini-mental state examination (MMSE) test and the Hospital Anxiety and Depression Scale (HADS) were administered for all RA patients with neutropenia as well as the control group. The frequencies of male patients, illiterate patients, patients living alone, patients with serious visual impairment, those with low income, and patients with high creatinine were significantly higher among RA patients with MTX-related neutropenia than in controls (p values <0.05). The RA patients with MTX-related neutropenia had significantly lower MMSE scores, and significantly higher HADS-A and HADS-D scores than controls (p values <0.05). In addition, the proportion of patients with probable dementia was significantly higher in RA patients with MTX-related neutropenia than in controls (p < 0.001). Twenty-six of the 37 patients (70.3 %) developed neutropenia with daily dosing. Patients who used MTX daily were more likely to be living alone than those using weekly dosing (p = 0.011). Multivariate analysis showed that having probable dementia on the MMSE test (OR 52.6), low income level (OR 56.8) and age (OR 1.12) were independent risk factors for the development of MTX-related neutropenia. The presence of probable dementia on MMSE, low socioeconomical status and older age are associated with serious toxicity in RA patients using MTX. Measures should be taken to prevent wrong MTX dosing by the patients. Compliance and patient education is of major importance, in particular, in the patients presented in this study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743624     DOI: 10.1007/s00296-013-2792-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

Review 1.  Methotrexate for rheumatoid arthritis patients who are on hemodialysis.

Authors:  Hasanein Al-Hasani; Euthalia Roussou
Journal:  Rheumatol Int       Date:  2011-07-22       Impact factor: 2.631

2.  [Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population].

Authors:  Can Güngen; Turan Ertan; Engin Eker; Resmiye Yaşar; Funda Engin
Journal:  Turk Psikiyatri Derg       Date:  2002

Review 3.  Long-term safety of methotrexate in the treatment of rheumatoid arthritis.

Authors:  Y Yazici
Journal:  Clin Exp Rheumatol       Date:  2010-10-28       Impact factor: 4.473

4.  Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination.

Authors:  D W Molloy; E Alemayehu; R Roberts
Journal:  Am J Psychiatry       Date:  1991-01       Impact factor: 18.112

5.  Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment.

Authors:  G S Alarcón; I C Tracy; W D Blackburn
Journal:  Arthritis Rheum       Date:  1989-06

6.  Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.

Authors:  Prabha Ranganathan; Robert Culverhouse; Sharon Marsh; Ami Mody; Tiffany J Scott-Horton; Richard Brasington; Amy Joseph; Virginia Reddy; Seth Eisen; Howard L McLeod
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

7.  Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel.

Authors:  Edna Efrati; Hela Elkin; Sagi Nahum; Norberto Krivoy
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

8.  Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.

Authors:  Olga A Malysheva; Matthias Wahle; Ulf Wagner; Matthias Pierer; Sybille Arnold; Holm Häntzschel; Cristoph G O Baerwald
Journal:  J Rheumatol       Date:  2008-04-15       Impact factor: 4.666

9.  Anxiety in rheumatoid arthritis.

Authors:  Melanie M VanDyke; Jerry C Parker; Karen L Smarr; James E Hewett; Gail E Johnson; James R Slaughter; Sara E Walker
Journal:  Arthritis Rheum       Date:  2004-06-15

10.  Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.

Authors:  G S Alarcón; I C Tracy; G M Strand; K Singh; M Macaluso
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

View more
  3 in total

Review 1.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

2.  Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide.

Authors:  Manoj Paul; Mahadevappa Hemshekhar; Ram M Thushara; Mahalingam S Sundaram; Somanathapura K NaveenKumar; Shivanna Naveen; Sannaningaiah Devaraja; Kumar Somyajit; Robert West; Siddaiah C Nayaka; Uzma I Zakai; Ganesh Nagaraju; Kanchugarakoppal S Rangappa; Kempaiah Kemparaju; Kesturu S Girish
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

3.  Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome.

Authors:  George E Fragoulis; Caron Paterson; Ashley Gilmour; Mohammad H Derakhshan; Iain B McInnes; Duncan Porter; Stefan Siebert
Journal:  RMD Open       Date:  2018-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.